Head-To-Head Comparison: MediPharm Labs (OTCMKTS:MEDIF) and Verrica Pharmaceuticals (NASDAQ:VRCA)

MediPharm Labs (OTCMKTS:MEDIF) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for MediPharm Labs and Verrica Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediPharm Labs	0	0	0	0	0.00
Verrica Pharmaceuticals	1	1	2	0	2.25

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 191.75%. Given Verrica Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than MediPharm Labs.

Earnings & Valuation

This table compares MediPharm Labs and Verrica Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediPharm Labs	N/A	N/A	N/A	N/A	N/A
Verrica Pharmaceuticals	$30.32 million	2.82	-$17.89 million	($1.67)	-2.98

MediPharm Labs has higher earnings, but lower revenue than Verrica Pharmaceuticals.

Institutional & Insider Ownership

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares MediPharm Labs and Verrica Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediPharm Labs	N/A	N/A	N/A
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Summary

Verrica Pharmaceuticals beats MediPharm Labs on 6 of the 9 factors compared between the two stocks.

About MediPharm Labs

MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.